TABLE 2.

Multivariable analysis of factors associated with extended progression free survival (PFS), and overall survival (OS)

	HR	[95% CI]	p
PFS
Absence of extramedullary disease	0.10	0.03–0.32	<0.001
Treatment program including autotransplant	0.46	0.30–0.73	0.001
Achievement of sFLCR normalization	0.46	0.28–0.73	0.001
Achievement of CR	0.48	0.30–0.78	0.003
ISS stage I/II	0.54	0.36–0.80	0.003
Absence of t(4;14) and t(14;16) and del(17p)	0.57	0.38–0.84	0.005
OS
Absence of extramedullary disease	0.04	0.01–0.14	<0.001
Achievement of sFLCR normalization	0.44	0.26–0.76	0.003
ISS stage I/II	0.48	0.30–0.78	0.003
Treatment program including autotransplant	0.44	0.25–0.77	0.004
Creatinine <1.2 mg/dL	0.61	0.37–0.99	0.046

Abbreviations: CR, complete response; ISS, international staging system; sFLCR, serum‐free light chain ratio.